HUP0303029A2 - CGMP-5 PDE inhibitorokat tartalmazó gyógyszerkészítmények alkalmazása sebek kezelésére - Google Patents

CGMP-5 PDE inhibitorokat tartalmazó gyógyszerkészítmények alkalmazása sebek kezelésére

Info

Publication number
HUP0303029A2
HUP0303029A2 HU0303029A HUP0303029A HUP0303029A2 HU P0303029 A2 HUP0303029 A2 HU P0303029A2 HU 0303029 A HU0303029 A HU 0303029A HU P0303029 A HUP0303029 A HU P0303029A HU P0303029 A2 HUP0303029 A2 HU P0303029A2
Authority
HU
Hungary
Prior art keywords
inhibitors
wounds
treatment
5pde
pharmaceutical compositions
Prior art date
Application number
HU0303029A
Other languages
English (en)
Inventor
Michael John Davies
Jonathan Paul Huggins
Dinah Velta Parums
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0303029A2 publication Critical patent/HUP0303029A2/hu
Publication of HUP0303029A3 publication Critical patent/HUP0303029A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány tárgya 5-ös típusú ciklikus guanozin-3',5'monofoszfát(cGMP 5-PDE) inhibitorok (a továbbiakban 5-PDE-inhibitorok) -elsősorban szildenafil - alkalmazása nem cukorbetegség okozta krónikussebek - elsősorban krónikus vénás fekélyek, krónikus felfekvés(dekubitusz-fekély), artériás fekélyek, valamint akut sebekkezelésére. Ó
HU0303029A 2000-08-21 2001-08-16 Use of pharmaceutical compositions containing cgmp-5pde inhibitors for treatment of wounds HUP0303029A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020588.0A GB0020588D0 (en) 2000-08-21 2000-08-21 Treatment of wounds
PCT/IB2001/001470 WO2002015893A2 (en) 2000-08-21 2001-08-16 Treatment of wounds

Publications (2)

Publication Number Publication Date
HUP0303029A2 true HUP0303029A2 (hu) 2003-12-29
HUP0303029A3 HUP0303029A3 (en) 2004-11-29

Family

ID=9898022

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303029A HUP0303029A3 (en) 2000-08-21 2001-08-16 Use of pharmaceutical compositions containing cgmp-5pde inhibitors for treatment of wounds

Country Status (10)

Country Link
EP (1) EP1311252A2 (hu)
JP (1) JP2004519425A (hu)
KR (1) KR20030097778A (hu)
AU (1) AU2001276636A1 (hu)
CA (1) CA2415791A1 (hu)
GB (1) GB0020588D0 (hu)
HU (1) HUP0303029A3 (hu)
IL (1) IL154011A0 (hu)
WO (1) WO2002015893A2 (hu)
ZA (1) ZA200301156B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
TWI339578B (en) 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
GB2459098A (en) * 2008-04-08 2009-10-14 Ethicon Inc Genetic markers of wound development
US20120065165A1 (en) * 2008-10-31 2012-03-15 Arginetix, Inc Compositions and methods of treating endothelial disorders
EP2556820A4 (en) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2333041A (en) * 1998-01-13 1999-07-14 Johnson & Johnson Medical Ltd Wound Composition
AU1025899A (en) * 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
KR20010093828A (ko) * 1998-12-14 2001-10-29 셀러지 파마세우티칼스, 인크 항문직장 질환 치료용 조성물 및 치료 방법
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
CA2411008C (en) * 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
JP2004511433A (ja) * 2000-06-30 2004-04-15 ファイザー・インク 末梢血管疾患、末梢ニューロパシー、及び自律性ニューロパシーの処置方法
IL154202A0 (en) * 2000-07-31 2003-07-31 Cellegy Pharma Inc Pharmaceutical compositions for treating anorectal disorders

Also Published As

Publication number Publication date
AU2001276636A1 (en) 2002-03-04
GB0020588D0 (en) 2000-10-11
JP2004519425A (ja) 2004-07-02
WO2002015893A3 (en) 2003-03-13
EP1311252A2 (en) 2003-05-21
CA2415791A1 (en) 2002-02-28
WO2002015893A2 (en) 2002-02-28
ZA200301156B (en) 2004-04-16
HUP0303029A3 (en) 2004-11-29
IL154011A0 (en) 2003-07-31
KR20030097778A (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
TR200103493T2 (tr) Metaloproteaz önleyicileri
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
HUP0301749A2 (hu) Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk
IS6585A (is) Hindrar fyrir mennskt fosfatidýl ínósítól-3-kínasa delta
HUP0401998A2 (hu) PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
DK1438052T3 (da) Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta
ATE480244T1 (de) Neue, hyaluronsäure oder hyaluronsaure derivate und collagenase enthaltende pharmazeutische zusammensetzungen zur topischen behandlung von wunden, verbrennungen und geschwüren
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
BR0213292A (pt) tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
HUP0303029A2 (hu) CGMP-5 PDE inhibitorokat tartalmazó gyógyszerkészítmények alkalmazása sebek kezelésére
DE60228722D1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
DE60114819D1 (de) Thrombomodulin analoga und ihre pharmazeutische verwendung
SE0004101D0 (sv) New use
DK1305037T3 (da) Smertestillende medikament
PT768084E (pt) Inibidor da metastese cancerosa
AU7362587A (en) Variants of alpha1-antitrypsin which are useful, in particular, as kallikrein inhibitors
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
PT1047413E (pt) Composição farmacêutica incluindo pelo menos um inibidor da aminopeptidase a
HUP0302880A2 (hu) Egy ciklusos depszipeptid javított aktivitással rendelkező kristályos formáját tartalmazó gyógyászati készítmények
ES2158887T3 (es) Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona.
DE60106890D1 (de) Verwendung von cdp-choline zur behandlung des alkoholentzugsyndroms
BR0111215A (pt) Métodos para prevenção de úlceras e aperfeiçoamento de desempenho fisiológico
ATE127344T1 (de) Aldosereduktasehemmer enthaltende zubereitungen zur behandlung von geschwüren.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees